These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 23415374)
1. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes. Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374 [TBL] [Abstract][Full Text] [Related]
2. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935 [TBL] [Abstract][Full Text] [Related]
3. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Mitiushkina NV; Iyevleva AG; Poltoratskiy AN; Ivantsov AO; Togo AV; Polyakov IS; Orlov SV; Matsko DE; Novik VI; Imyanitov EN Cancer Cytopathol; 2013 Jul; 121(7):370-6. PubMed ID: 23408463 [TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350 [TBL] [Abstract][Full Text] [Related]
5. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. Tian L; Suzuki M; Nakajima T; Kubo R; Sekine Y; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T; Yoshino I; Cancer; 2008 Sep; 113(6):1396-403. PubMed ID: 18666211 [TBL] [Abstract][Full Text] [Related]
7. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Mizuno K; Osada H; Konishi H; Tatematsu Y; Yatabe Y; Mitsudomi T; Fujii Y; Takahashi T Oncogene; 2002 Apr; 21(15):2328-33. PubMed ID: 11948416 [TBL] [Abstract][Full Text] [Related]
8. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301 [TBL] [Abstract][Full Text] [Related]
10. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476 [TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973 [TBL] [Abstract][Full Text] [Related]
12. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325 [TBL] [Abstract][Full Text] [Related]
13. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017 [TBL] [Abstract][Full Text] [Related]
14. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas. Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104 [TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792 [TBL] [Abstract][Full Text] [Related]
18. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome. Gao L; Liu F; Zhang H; Sun J; Ma Y Genes Chromosomes Cancer; 2016 Feb; 55(2):158-68. PubMed ID: 26542416 [TBL] [Abstract][Full Text] [Related]
19. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]